Search
for
Sort by
Research 541–570 of 1000+
- 260 Anti-OX40 monoclonal antibody IMG-007 exhibited clinical activity of hair regrowth, suppressed scalp inflammatory biomarkers in patients with severe alopecia areata in a Ph1b/2a study
- 61346 Baseline Psychosocial Impact of Disease in Patients with Severe Alopecia Areata Treated with Baricitinib Recruited from the US Customer Support Program
- 63407 A Descriptive Analysis of Patients With Moderate-to-Severe Atopic Dermatitis and Comorbid Alopecia Areata in the Abrocitinib JADE Clinical Program
- Response to Pavlović ’s “Response to Li et al.’s ‘Therapeutic efficacy of platelet-rich plasma combining with microneedling and topical minoxidil in refractory severe androgenic alopecia’”
- 0350 Impact of switching janus kinase inhibitors in the treatment of severe alopecia areata
- BH06 (P075) A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
- <i>PIK3CA</i> gain-of-function mutation in Schwann cells leads to severe neuropathy and aerobic glycolysis through a non-cell autonomous effect
- Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute
- Efficacy and Safety of Long‐Term Azathioprine Therapy for Severe Alopecia Areata: A 10‐Year Cohort Study
- Predictive factors for treatment responses to baricitinib in severe alopecia areata: A retrospective, multivariate analysis of 70 cases from a single center
- Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
- Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
- Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study
- Using high-intensity phototechnology as a method of treating mild to severe diffuse alopecia
- Asymptomatic SARS-COV2 Infection or COVID-19 vaccination effect for severe multisystem inflammatory syndrome in a 6-year-old girl: case report and review of the literature
- Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study
- Tissue expansion and follicular unit extraction hair restoration in rehabilitation of a severe postburn deformity of neck and beard region
- Assessing a measure for Quality of Life in patients with severe Alopecia Areata: a multicentric Italian study
- LB1040 Machine learning-based predictive model with routine blood work identifies moderate-severe alopecia areata
- Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Efficacy of tofacitinib as an induction agent in severe alopecia areata compared to oral betamethasone weekly pulse
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
- Efficacy and Safety of Topical Corticosteroid Treatment under Occlusion for Severe Alopecia Areata in Children. A single-center retrospective analysis
- The effect of low-level laser therapy on severe acute respiratory syndrome coronavirus-2 infected cells
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study
- Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
- Effectiveness of oral tofacitinib treatment on patients with moderate‐to‐severe alopecia areata in Iran